These therapies involve programming the T-cell receptor (TCR) of T cells to recognize a specific peptide, or antigen, found on tumor cells. There are many efforts underway to identify the most ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...

Breakthrough nanovaccine uses tumor cell membranes and immune-boosting polymers to enhance personalized cancer immunotherapy, showing strong results in preclinical models.

IL-12 is produced in antigen-presenting cells and ... suppress or enhance tumor growth depending on the tumor microenvironment. Finally, the peptide increases IL-12p70 production from T cells ...

In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

These therapies involve programming the T-cell receptor (TCR) of T cells to recognize a specific peptide, or antigen, found on tumor cells. There are many efforts underway to identify the most ...

(6) Soluble TCR and TCR mimics are small proteins that bind peptides and engage with the CD3ε subunit of the endogenous TCR to create a synthetic immunological synapse. (7) A T cell antigen coupler ...

Different immunogenic antigens characterized in solid ... White blood cell; WT1: Wilms tumor gene 1. Interesting targets for peptide vaccination have been defined including Wilms tumor gene ...

In both, scientists showed that some tumor-specific antigens might be the result of transposable elements, also called “jumping genes,” sneaking into an mRNA molecule by tacking themselves onto exons.

The U.S. Food and Drug Administration (FDA) has approved Myrio Therapeutics' Investigational New Drug (IND) application for its lead product, PHOX2B PC-CAR T, paving the way for human trials in ...